Key result
Preemptive dexamethasone administration along with a further cycle of cytosine arabinoside successfully prevented the recurrence of massive pericardial effusion in an AML patient.
Why the study?
Does preemptive dexamethasone administration prevent cytosine arabinoside-induced acute pericarditis in an AML patient with prior massive pericardial effusion?
Case Report (n=1)
Does preemptive dexamethasone administration prevent cytosine arabinoside-induced acute pericarditis in an AML patient with prior massive pericardial effusion?
Preemptive dexamethasone administration may prevent the recurrence of cytosine arabinoside-induced acute pericarditis in patients requiring continued therapy.
Answers are grounded in this paper and cite their sources.
Supports dexamethasone with Ara-C rechallenge after prior effusion in AML; hypothesis-generating and leaves open broader applicability.
Pericarditis/pericardial effusion (PC/PEEF) is a rare but fatal complication of cytosine arabinoside (Ara-C). We report an acute myeloid leukemia (AML) patient who developed massive pericardial effusion after a second Ara-C exposure. As Ara-C was most beneficial in controlling the leukemia, she was treated with a further cycle of Ara-C along with dexamethasone to prevent the complication from reoccurring. No PC/PEEF was subsequently detected.
No takes yet. Share an insight, caveat, or question.
Owattanapanich et al. (2018) conducted a case report in Acute myeloid leukemia (AML) with Ara-C-induced pericardial effusion (n=1). Preemptive dexamethasone administration along with Ara-C was evaluated on Recurrence of pericarditis/pericardial effusion (PC/PEEF). Preemptive dexamethasone administration along with a further cycle of cytosine arabinoside successfully prevented the recurrence of massive pericardial effusion in an AML patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: